AXIM AXIM BIOTECHNOLOGIES, INC.

OTC Pharmaceutical Preparations NV CIK: 0001514946
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

AXIM is in severe financial distress with negative stockholders' equity of -9.5M, liabilities exceeding assets by 9.6M, and a cash position of only 6K despite long-term debt of 6M. The company is burning cash at an accelerating rate (-514K operating cash flow) while generating minimal revenue (70.5K), rendering it technically insolvent and at critical risk of bankruptcy without immediate capital restructuring.

Strengths

  • + Exceptional gross margin of 97.5% indicates strong unit economics on limited revenue
  • + Recent revenue growth of 345.3% YoY shows early commercial traction despite minimal absolute scale
  • + Pharmaceutical sector positioning may provide future revenue opportunities if operations stabilize

Risks

  • ! Negative stockholders' equity of -9.5M indicates technical insolvency and potential bankruptcy risk
  • ! Liquidity crisis with current ratio 0.00x and cash balance of 6K insufficient to cover operations
  • ! Severe cash burn of -514K operating cash flow with virtually no offsetting revenue generation
  • ! Long-term debt of 6M creates refinancing risk given negative equity and operational losses
  • ! Net losses of 2.6M on 70.5K revenue unsustainable; operating margins of -1378% indicate fundamental business model failure
  • ! Zero insider activity in 90 days suggests potential loss of confidence from management

Key Metrics to Watch

Financial Metrics

Revenue
70.5K
Net Income
-2.6M
EPS (Diluted)
$-0.01
Free Cash Flow
-516.9K
Total Assets
3.7M
Cash
6.0K

Profitability Ratios

Gross Margin 97.5%
Operating Margin -1,378.1%
Net Margin -3,636.4%
ROE N/A
ROA -68.7%
FCF Margin -733.6%

Balance Sheet & Liquidity

Current Ratio
0.00x
Quick Ratio
0.00x
Debt/Equity
N/A
Debt/Assets
355.8%
Interest Coverage
-2.84x
Long-term Debt
6.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-20T12:54:12.825121 | Data as of: 2024-06-30 | Powered by Claude AI